Fosun Kairos | 复星凯瑞

Being founded in 2017 and a division of Fosun Pharma, Shanghai Fosun Kairos Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise. Fosun Kairos, since its establishment, has committed to the R&D, industrialization and commercialization of cell therapies against tumors, with the mission of "Cure the Incurable, Enlighten the Life" and its vision to be a most valuable leading one in the field of cell and gene therapy. Fosun Kairos has introduced Yescarta®, a CAR-T therapy for treating relapsed or refractory non-Hodgkin lymphoma, from U.S. Kite Pharma and localized its production in China. In June 2021, Fosun Kairos received approval to launch China's first CAR-T therapy, YIKAIDA (Axicabtagene Ciloleucel Injection, a local version of Yescarta®). In June 2023, YIKAIDA was approved for another indication, i.e., the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. The launch of YIKAIDA marked the inaugural year of CAR-T therapy in China and continues to drive high-quality progress in lymphoma treatment. Fosun Kairos has established a cell-therapy R&D center and a technology platform covering over 2000 square meters in Zhangjiang, Shanghai. Assembling a team of skilled scientists with high academic qualification from both domestic and abroad, the Company is dedicated to the early-stage research and development as well as evidence-based clinical projects of CAR-T, through technology license-in, independent innovation and cooperative development, aiming to build a sustainable innovation pipeline in cell therapy. Looking forward, Fosun Kairos will function as the core platform for Fosun Pharma's cell therapy technologies, concentrating on tumor immunotherapy with a goal to reach the global market. It aims to become a worldwide leader in cell therapy, offering more hope for cures to patients globally.